Quarterly ResultJul 30, 2026, 06:33 AM
Regeneron Q2 Revenue +17% to $4.3B; Non-GAAP EPS $14.29
AI Summary
Regeneron Pharmaceuticals reported strong second-quarter 2026 financial results, with total revenues increasing 17% to $4.3 billion and non-GAAP diluted EPS growing 11% to $14.29. Key product sales saw significant growth, including Dupixent global net sales up 38% to $6.0 billion and EYLEA HD U.S. net sales up 52% to $596 million. The company also fully repaid its Sanofi Development Balance and announced regulatory acceptances for Cemdisiran, alongside other pipeline advancements and corporate updates.
Key Highlights
- Total revenues increased 17% to $4.3 billion in Q2 2026.
- Non-GAAP diluted EPS rose 11% to $14.29.
- Dupixent global net sales reached $6.0 billion, up 38%.
- EYLEA HD U.S. net sales grew 52% to $596 million.
- Libtayo global net sales increased 30% to $489 million.
- Sanofi Development Balance fully repaid as of Q2 2026 end.
- Cemdisiran regulatory submissions accepted by FDA and EMA for gMG.
- Repurchased $1.2 billion of common stock in Q2 2026.
Price Impact
More from REGN